Diabetes mellitus
Types of Diabetes
Diabetes mellitus type 1, Diabetes mellitus type 2, Gestational diabetes
Pre-diabetes: Impaired fasting glycaemia, Impaired glucose tolerance
Disease Management
Diabetes management: Diabetic diet, Anti-diabetic drugs, Conventional insulinotherapy, Intensive insulinotherapy
Blood tests
Fructosamine, Glucose tolerance test, Glycosylated hemoglobin

An anti-diabetic drug or oral hypoglycemic agent is used to treat diabetes mellitus. They usually work by lowering the glucose levels in the blood. There are different types of anti-diabetic drugs, and their use depends on the nature of the diabetes, age and situation of the person, as well as other factors.

Insulin, exenatide, and pramlintide are the only non-oral antidiabetic drugs. Insulin is the mainstay of treatment in Type I diabetes, in which insulin production is impaired. In Type II diabetes, Insulin is used when oral medication has become ineffective. Exenatide and pramlintide are new injectable medications approved in 2005 in the US by the FDA to treat Diabetes mellitus type 2.

Sulfonylureas

Sulfonylureas were the first widely used oral hypoglycemic medications. They are insulin secretagogues, triggering insulin release by direct action on the K_ATP channel of the pancreatic beta cells. Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" drugs are now more commonly used. They are more effective than first-generation drugs and have fewer side effects.

Sulfonylureas bind strongly to plasma proteins. Sulfonylureas are only useful in Type II diabetes, as they work by stimulating endogenous release of insulin. They work best with patients over 40 years old, who have had diabetes mellitus for under ten years. They can not be used with type I diabetes, or diabetes of pregnancy. They can be safely used with metformin or -glitazones. The primary side effect is hypoglycemia.

• First-generation agents
  
  • tolbutamide (Orinase)
    acetohexamide (Dymelor)
    tolazamide (Tolinase)
    chlorpropamide (Diabinese)
• Second-generation agents
  
  • glipizide (Glucotrol)
    glyburide (Diabeta, Micronase, Glynase)
    glimepiride (Amaryl)
    gliclazide (Diamicron)

Meglitinides

Meglitinides are related to sulfonylureas and of often called "short-acting secretagogues." The amplification of insulin release is shorter and more intense, and they are taken with meals to boost the insulin response to each meal.

• repaglinide (Prandin) - The max dosage is 16mg/day. Take this drug 0 to 30 minutes prior before eating a meal. If a meal is skipped, then the medication should also be skipped.
• nateglinide (Starlix) - The max dosage is 360 mg/day, usually 120 mg three times a day (TID). It also follows the same recommendations as repaglinide.

Adverse reactions include weight gain and hypoglycemia.

Biguanides

Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, metformin has become the most commonly used agent for type 2 diabetes in children and teenagers.

• metformin (Glucophage)
• Phenformin (DBI): used in 1960-1980s, withdrawn due to lactic acidosis risk.

Metformin should be temporarily discontinued before any radiographic procedure involving intravenous iodinated contrast as patients are at an increased risk of lactic acidosis.

Thiazolidinediones

Thiazolidinediones, also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of numerous genes regulating glucose and fat metabolism. They act as "insulin sensitizers" without increasing insulin secretion.

• rosiglitazone (Avandia)
  pioglitazone (Actos)
  troglitazone (Rezulin): used in 1990s, withdrawn due to hepatitis and liver damage risk.

Alpha glucosidase inhibitors

Alpha glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream more slowly, and can be matched more effectively by an impaired insulin response or sensitivity. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes.

• miglitol (Glyset)
  acarbose (Precose/Glucobay)

These medications are rarely used in the United States because of the severity of their side effects (flatulence and bloating). They are more commonly prescribed in Europe.

Incretin mimetic

Exenatide (also Exendin-4, marketed as Byetta) is the first of a new class of medications approved for the treatment of type 2 diabetes. It is to be used in conjunction with oral medications such as metformin and/or a sulfonylurea to improve glucose control. The medication is injected twice per day using a specially designed pen. The typical human response is both an improvement of the release of internal insulin by the pancreas and suppression of pancreas glucagon release, behaviors more typical of individuals without blood sugar control problems. In the presence of exenatide, these responses are greater when the blood sugar is elevated.

DPP-4 inhibitors

• Dipeptidyl peptidase-4 (DPP-4) inhibitors (vildagliptin, sitagliptin) increase blood concentration of GLP-1 (glucagon-like peptide-1).

Amylin analogue

• Pramlintide.

Experimental agents

Many other potential drugs are currently in investigation by pharmaceutical companies. Some of these are simply newer members of one of the above classes, but some work by novel mechanisms. For example, at least one compound that enhances the sensitivity of glucokinase to rising glucose is in the stage of animal research. Others are undergoing phase I/II studies.

• PPARα/γ ligands (muraglitazar and tesaglitazar) - development stopped due to adverse risk profile
• SGLT (sodium-dependent glucose transporter 1) inhibitors increase urinary glucose.
• FBPase (fructose 1,6-bisphosphatase) inhibitors decrease gluconeogenesis in liver.

Insulin by mouth

The basic appeal of oral hypoglycemic agents is that most people would prefer a pill to an injection. Unlike all the oral drugs described in this article, insulin is a protein. Protein hormones, like meat proteins, are digested in the stomach and gut. One alternative delivery method is by inhalation. In 2006 the U.S. Food and Drug Administration approved the use of Exubera, the first inhalable insulin.

However, the potential market for an oral form of insulin is enormous and many laboratories have attempted to devise ways of moving enough intact insulin from the gut to the portal vein to have a measurable effect on blood sugar. One can find several research reports over the years describing promising approaches or limited success in animals, and limited human testing, but as of 2004, no products appear to be successful enough to bring to market.[1]

Herbal extracts

The first registred use of anti-diabetic drugs was as herbal extracts used by indians in the Amazon Basin for the treatment of type 2 diabetes, and today promoted as vegetable insulin although not formally an insulin analog.[1] The major recent development was done in Brazil around Myrcia sphaerocarpa and other Myrcia species.

"Many countries, especially in the developing world, have a long history of the use of herbal remedies in diabetes (...) STZ diabetic rats were also used to test Myrcia Uniflora extracts (...) ".

The usual treatment is with concentrated (root) Myrcia extracts, commercialized in a 4 US dollar per kilogram packed rocks (~100 times cheaper than equivalent artificial drugs), named "Pedra hume de kaá". Phytochemical analysis of the Myrcia extracts reported kinds of flavanone glucosides (myrciacitrins) and acetophenone glucosides (myrciaphenones), and inhibitory activities on aldose reductase and alpha-glucosidase.

A recent review article presents the profiles of plants with hypoglycaemic properties, reported in the literature from 1990 to 2000 and states that "Medical plants play an important role in the management of diabetes mellitus especially in developing countries where resources are meager."

References

• Lebovitz HE. Therapy for Diabetes Mellitus and Related Disorders. 4th edition. Alexandria:American Diabetes Association, 2004.
• Holland, Norman & Adams, Michael Patrick. Core Concepts in Pharmacology. Pearson Education, Inc. New Jersey. 2003.
• Soumyanath, Amala(ed.) (2005-11-01). Traditional Medicines for Modern Times, 1st Edition (in english), Taylor & Francis. ISBN 0415334640.
• McNeill, John H. (1999-02-01). Experimental Models of Diabetes, 1st Edition (in english), CRC Press, 208. ISBN 0849316677.
• Matsuda, H, Nishida N, Yoshikawa M. (Mar 2002). "Antidiabetic principles of natural medicines. V. Aldose reductase inhibitors from Myrcia multiflora DC. (2): Structures of myrciacitrins III, IV, and V.". Chem Pharm Bull (Tokyo) 50(3): 429-31.
• Bnouham M et al (2006). "Medicinal plants with potential antidiabetic activity - A review of ten years of herbal medicine research (1990-2000)". Int J Diabetes & Metabolism 14: 1-25.

This guide is licensed under the GNU Free Documentation License. It uses material from the Wikipedia.

Video: FDA Approves First Inhaled Insulin

Domain parking is an advertising practice used primarily by domain name registrars and internet advertising publishers to monetize type-in traffic visiting an under-developed domain name. The domain name will usually resolve to a page containing relevant advertising listings and links. These links will be targeted to the predicted interests of the visitor and may change dynamically based on the results that visitors click on. Usually the domain owner is paid based on how many links have been visited (e.g. pay per click) and on how beneficial those visits have been. The keywords for any given domain name provide clues as to the intent of the visitor before arriving.

Another use of domain parking is to be a placeholder of an existing web site. A company might choose to use this method to redirect its website traffic to another web site it owns.

Expired domains that were formerly websites are also sought after for domain parking. A domain that was used as a website and is allowed to expire will still maintain most of its prior inbound links. These types of domains usually start off with their largest amount of visitor traffic initially after being claimed from the domain drop lists. As website operators and search engines begin to remove the former inbound links, the traffic to the parked domain will begin to decline.

On domains with a 'one-click' implementation, a click on a keyword is not necessary to generate ads. The ads are targeted based on the domain name.

Domains with 'two-click' implementations require a click on a keyword or a keyword search to generate ads.

Domain parking can be classified as monetized and non-monetized. In the former, ads are shown to visitors and the domain is 'monetized'. In the latter, an "Under Construction" or a "Coming Soon" message is put up on the domain. This a single page web site that people see when they type the domain name in a web browser. This is one quick way for getting an Internet presence. Domain names can be parked before a web site is ready for launching.

There are several companies that actively cater to domain name owners and act as middlemen to serve advertisements on parking pages. The parking pages are propagated automatically on a domain owner's web property when they either change the name servers or forward the URL.

Links

• The Death of Domain Parking?, from Slashdot.org

This guide is licensed under the GNU Free Documentation License. It uses material from the Wikipedia.

Video: Reviews of Domain Parking Services